Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for October 20, 2020

10/20/2020

 
Regulatory Update
 
The FDA approved a combination of three Ebola monoclonal antibodies, atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb, Regeneron) for the treatment of Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
 
The FDA designated Inventiva’s lanifibranor a Breakthrough Therapy for the treatment of non-alcoholic steatohepatitis (NASH).
 
Scynexis submitted an NDA for ibrexafungerp for the treatment of vulvovaginal candidiasis.
 
The EMA has granted PRIME status to Akero’s efruxifermin for the treatment of NASH.
 
CHMP recommended approval to EMA of Alnylam’s lumasiran for the treatment of hyperoxaluria type 1.
 
CHMP recommended approval to EMA of the long-acting injectable combination of ViiV’s cabotegravir (Vocabria) and Janssen’s rilpivirine (Rekambys) for the treatment of Human Immunodeficiency Virus type 1.
 
Announced Research Updates
 
Gilead and Galapagos announced results from the 58-week, 1,348 patient, Phase IIb/III, SELECTION trial that evaluated filgotinib as a treatment of moderately to severely active ulcerative colitis. 
  • During the first 10 weeks of the trial patients received filgotinib 100 mg, 200 mg or placebo. Treatment with filgotinib 100 mg did not differ from placebo in the percentage of patients achieving remission. However, compared to placebo, remission was achieved in more biologic-naive patients treated with filgotinib 200 mg (26.1% vs. 15.3%) and in biologic-experienced patients (11.5% vs. 4.2%). 
  • The 558 patients that achieved remission were re-randomized to filgotinib or placebo for an additional 48 weeks. In the maintenance part of the trial, 37.2% of patients treated with filgotinib 200 mg achieved clinical remission compared to 11.2% with placebo
After failure in the Phase III, LAUREL trial, Roche discontinued development of etrolizumab as a treatment for ulcerative colitis.
 
Lysogene is investigating the death of one of 18 patients that received LYS-SAF302 in the Phase II/III AAVance trial. LYS-SAF302 is a gene therapy that provides the SGSH gene, to produce an enzyme that is absent in children with Sanfilippo syndrome.
 
Astex and Otsuka announced that guadecitabine did not improve overall survival in 302 acute myeloid leukemia patients in the Phase III ASTRAL-2 trial or in 417 myelodysplastic syndrome/chronic myelomonocytic leukemia patients in the Phase III ASTRAL-3 trial.
 
Revance announced that in the 36-week, 301 patient, Phase III, ASPEN-1 trial, treatment with a single dose of daxibotulinumtoxinA resulted in a decrease in the average Toronto Western Spasmodic Torticollis Rating Scale scores at weeks four and six of 12.7 points with 125 units and 10.9 points with 250 units compared to 4.3 points with placebo in patients with cervical dystonia. Researchers estimated the median duration of effect as 24.0 weeks with 125 units and 20.3 weeks with 250 units, which corresponded to a loss of 80% of the peak treatment effect.
 
Published Research Updates
 
A 9,302 patient, Phase III trial was stopped early after an interim analysis failed to find a benefit with Sanofi Pasteur’s Clostridium difficile vaccine compared to placebo in preventing symptomatic C. difficile infection (0.29 infections per 100 person-years vs 0.28 infections per 100 person-years) in patients 50 years or older who were at high risk of C difficile infection.
 
In a 35-week, 135 patient, open label extension of Amylyx Pharmaceuticals’ CENTAUR trial, all patients received AMX0035 during the extension, where, overall survival was 25 months in patients that originally received AMX0035 for the first 24-weeks and 18.5 months for those who originally received placebo.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.